Brucellosis Vaccines Market to Surpass US$ 324.83 Mn by 2030 - Coherent Market Insights

The Global Brucellosis Vaccines Market, by Type (RB51 Vaccine, S19 Vaccine, B19 Vaccine and Others (45/20 vaccine, SR82 vaccine, etc.)), by Application (Cattle, Sheep, Goat and Others (swine, horses, etc.)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 224.64 million in 2022 and expected to exhibit a CAGR of 4.7%  over the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.

Increasing government initiatives such as the launch of vaccination programs is expected to be the major factor driving growth of global brucellosis vaccines market over the forecast period. For instance, in January 2022, the Nagaland department of Animal Husbandry and Veterinary Services (AH&VS) India launched the brucellosis vaccination program in the state. As brucellosis is a bacterial zoonotic disease, high brucellosis prevalence in animals may pose a greater risk of disease transmission to animal handlers and veterinarians. This brucellosis control program is a central sponsored scheme (CSS), an initiative by the Prime Minister of India. This is strictly monitored by the government of India.

Global Brucellosis Vaccines Market – COVID-19 Impact (Impact on Manufacturing)

The outbreak of the COVID-19 pandemic has certainly impacted the global brucellosis vaccines market. The lockdown has compelled veterinaries to close their operations, or even if the veterinarians were open, the public was afraid to visit veterinarians for vaccination during the meantime. Also, the consumption of meat and dairy products decreased during the outbreak, which in turn, has impacted the expansion of livestock across the globe.

The coronavirus or COVID-19 outbreak started from Wuhan, China in 2019 and has spread across all the continents of the world, affecting various industries. The economy of countries such as India, Italy, Bangladesh, Sri Lanka, the U.S., Morocco, and others has been disrupted due to lockdowns implemented by governments to combat the spread of coronavirus since 2020. According to data published by the Organization for Economic Co-operation and Development (OECD) in November 2020, the COVID-19 has posed major challenges to the healthcare infrastructure in the Middle East & North Africa region. Some countries such as Lebanon, Morocco, and Tunisia have been severely impacted with regards to the overall management of the COVID-19 crisis. Moreover, OECD stated that countries such as Iran, Syria, Iraq, the Palestinian Authority, Yemen, and Libya faced the lack of hospital beds and low COVID-19 testing capacity. According to an article published by the Elsevier Public Health Emergency Collection journal in November 2020, it was estimated that during the COVID- 19 pandemic, hospitals and healthcare systems in America (North America and Latin America) lost a revenue of around US$ 202.6 billion which is generated from providing healthcare services.

Browse 26 Market Data Tables and 28 Figures spread through 149 Pages and in-depth TOC on “Brucellosis Vaccines Market”- Global Forecast to 2030, by Type (RB51 Vaccine, S19 Vaccine, B19 Vaccine and Others (45/20 vaccine, SR82 vaccine, etc.)), by Application (Cattle, Sheep, Goat and Others (swine, horses, etc.)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the Global Brucellosis Vaccines Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/brucellosis-vaccines-market-5038

Key Takeaways of the Global Brucellosis Vaccines Market:

• Global brucellosis vaccines market is expected to exhibit a CAGR of 4.7% over the forecast period, owing to increasing prevalence of brucellosis, which is expected to drive the growth of the market over the forecast period. For instance, according to an article published by the National Center for Biotechnology Information, a series of databases relevant to biotechnology and biomedicine, a sample of cattle from nine selected sectors of Nyagatare, Rwanda, was tested for brucellosis. The prevalence of brucellosis in herds consisting cows with no history of abortion was 38.5% and 17.0% in those with a history of abortion.
• Among type, the RB51 Vaccine segment is expected to account for the largest market share in 2022, RB51 is the approved B. abortus vaccine strain most commonly used to protect cattle against infection and abortion.
• Increasing prevalence of brucellosis is expected to drive the segment growth over the forecast period. For instance, according to an article published by National Center for Biotechnology Information in 2018, the prevalence of brucellosis in crossbreed cattle was 23.6% and in indigenous cattle was 13.8% in Nyagatare District, Eastern Province, Rwanda.
• Key players operating in the global brucellosis vaccines market include Merck & Co., , CZ Vaccines, Colorado Serum Company, Indian Immunologicals Ltd., Hester Biosciences Limited, Veterinary Technologies Corporation, Jordan Bio-industries Center, Laboratorios Tornel, Fivet Animal Health and VETAL Animal Health Products Inc.